Moderna, Inc.
200 Technology Square
Cambridge, MA
United States
Tel: 617-714-6500
Website: https://modernatx.com/
Email: careers@modernatx.com
About Moderna, Inc.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
mRNA is now a turning point in the history of science, medicine, technology, even humankind itself. With this breakthrough discovery, many of the world’s biggest and most challenging medical problems are no longer a question of “how?” but merely a question of “when?”
Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine.
Stock Symbol:
MRNA
Stock Exchange:
USNASDAQ GS
Moderna employees share their thoughts on our culture, values and mission. To hear additional employee stories and learn more about our inclusive and innovative benefits offerings, visit us on our website.
1011 articles with Moderna, Inc.
-
Pfizer and BioNTech reported positive data Friday from their Omicron BA.4/BA.5-adapted bivalent booster. This followed a similar announcement by Moderna Monday.
-
RSV, influenza, COVID-19 and monkeypox have dominated vaccine discussions this year, but vaccines are also being developed for a host of other infectious diseases.
-
BioSpace's 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
-
The past few weeks have seen changes that will impact the biopharma industry surrounding salaries and pay. To learn about job opportunities at some of the industry's top companies, see inside.
-
Moderna is dropping an IL-12 program in autoimmune disorders after AstraZeneca returned the rights, the mRNA leader announced Thursday in its third quarter filing.
-
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
11/1/2022
Moderna, Inc. announced that it has received approval from the Ministry of Health, Labour and Welfare in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.222 in adults 18 years and older.
-
Moderna Named a Top Employer by Science for Eighth Consecutive Year
10/27/2022
Moderna, Inc. announced it was ranked one of the top employers in the global biopharmaceutical industry by Science and Science Careers' 2022 Top Employers Survey for the eighth consecutive year.
-
Moderna to Host First Environmental, Social and Governance (ESG) Day on November 10, 2022
10/27/2022
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it will host its first virtual ESG Day for analysts and investors at 9:00 a.m. ET on Thursday, November 10.
-
EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union
10/19/2022
Moderna, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending a variation to the conditional marketing authorization to include a 25 µg two-dose series of Spikevax for active immunization to prevent coronavirus disease 2019 caused by SARS-CoV-2 in children 6 months to 5 years.
-
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union
10/19/2022
Moderna, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional marketing authorization for mRNA-1273.222 as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older, who have previously received at least a primary vaccination course against COVID-19.
-
Analysis Shows Moderna’s Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster
10/19/2022
Moderna, Inc. today announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214.
-
Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries
10/17/2022
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and Gavi, the Vaccine Alliance, have mutually agreed to cancel remaining pending orders under the current COVID-19 vaccine supply agreement for 2022.
-
Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022
10/13/2022
Moderna, Inc. today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 3, 2022 to report its third quarter 2022 financial results, and provide a corporate update.
-
Merck and Moderna are moving forward with a personalized cancer vaccine as Merck exercised its option to develop and commercialize mRNA-4157/V940, the companies announced Wednesday.
-
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age
10/12/2022
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it has received emergency use authorization from the U.S. Food and Drug Administration for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children and adolescents 6 to 17 years of age.
-
Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine
10/12/2022
Moderna, Inc. and Merck today announced that Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing Collaboration and License Agreement.
-
As it gears up to launch several new products, Moderna has created a new leadership role and onboarded an industry veteran.
-
Moderna Creates New Executive Committee Role Ahead of New Product Launches
9/29/2022
Moderna, Inc. today announced that the Company has expanded the Executive Committee to prepare for multiple upcoming new product launches.
-
European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine
9/28/2022
Moderna, Inc. announced that the European Medicines Agency has accepted a variation for the evaluation of a 50 µg booster dose of the Omicron-containing bivalent COVID booster candidate, mRNA-1273.222 in adults 12 years and older.
-
In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.